Jupiter Neurosciences Signs Up to $100 Million Deal for Exclusive U.S. Rights to Psychedelic MDMA Formulation

Corporate ActionRegulation
โดย IPO Edge·Read original
Summary · why it matters

Jupiter Neurosciences has signed a definitive licensing agreement with PharmAla Biotech for perpetual exclusive U.S. rights to ALA-002, a patented formulation of MDMA, in a deal valued at up to $100 million including milestones. The transaction transforms Jupiter into a dual clinical-stage CNS company, adding ALA-002 to its existing Phase II Parkinson's disease program for JOTROL, a proprietary enhanced bioavailability resveratrol formulation. Chairman and CEO Christer Rosén and President Alison Silva discussed the acquisition during a fireside chat hosted by IPO Edge, noting the primary indication for ALA-002, its addressable market size, and potential revenue relative to the acquisition cost. They also addressed the status of the Phase II Parkinson's trial, the evolving U.S. regulatory landscape for psychedelics, and key milestones across the company's portfolio.

Impact on stocks 5

Psychedelic Medicine▲ · 3 stocks
Biotech & Genomic Medicine▲ · 1 stocks
Information Technology▲ · 1 stocks

Theme Impact 1

Off-coverage companies 2

IPO EdgePrivate± Mixed
relevance

PharmAla Biotech HoldingsPrivate± Mixed
relevance

Related news

Three Psychedelic Stocks With Potential Clinical Trial Catalysts

Optimi Health, AtaiBeckley, and COMPASS Pathways are three psychedelic medicine companies with upcoming clinical trial catalysts that could reshape their risk-reward profiles. Optimi Health, a Canadian manufacturer with a Health Canada-licensed GMP facility, is already shipping pharmaceutical-grade MDMA and psilocybin into Australia's reimbursed prescription market, though its revenue remains below CA$1 million. AtaiBeckley has multiple Phase 2 programs targeting treatment-resistant depression and social anxiety, with Phase IIb data expected in 2026 and potential progression to Phase 3 trials, but it faces widening losses and high funding risk. COMPASS Pathways is advancing its psilocybin therapy COMP360 in Phase III for treatment-resistant depression and plans to file a rolling NDA with the FDA, yet it remains pre-revenue with a history of shareholder dilution.
OPTH ▲ATAI
Psychedelic Medicine
Simply Wall St·71dRead more →

PharmAla Completes GMP Manufacture of ALA-002 Drug Substance

PharmAla Biotech Holdings has completed GMP production of the drug substance for its lead candidate ALA-002. The company plans to use the substance to advance ALA-002 through clinical activities worldwide and for commercialization in Australia via its subsidiary Cortexa, co-owned by Vitura Health. PharmAla focuses on developing MDXX class molecules, including MDMA, in highly titrated forms for treating neurobiological and mental disorders. The stock closed at $0.14 on the Canadian Stock Exchange, up 3.57%.
Psychedelic Medicine
RTTNews·73dRead more →
© 2026 MarketDXNews